The importance of atrial fibrillation burden and the origin of device-tailored anticoagulation

Peter Zimetbaum*, Ethan R. Ellis, Jonathan W. Waks, Rod S Passman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

The current paradigm for anticoagulation in patients with atrial fibrillation is based upon clinical risk factors for stroke without reference to the frequency or duration (i.e., burden) of atrial fibrillation episodes. In the last decade, increasing evidence derived from device-based surveillance of atrial fibrillation has suggested that in some patients the burden of atrial fibrillation may be associated with thromboembolic risk. The development of rapidly acting oral anticoagulants and devices with remote monitoring capability has allowed the testing of a strategy of tailored or "pill-in-the- pocket" anticoagulation based upon atrial fibrillation burden.

Original languageEnglish (US)
Pages (from-to)1319-1324
Number of pages6
JournalPACE - Pacing and Clinical Electrophysiology
Volume36
Issue number11
DOIs
StatePublished - Nov 1 2013

Keywords

  • atrial fibrillation
  • clinical trials
  • electrophysiology - clinical

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The importance of atrial fibrillation burden and the origin of device-tailored anticoagulation'. Together they form a unique fingerprint.

Cite this